iShares iBonds Dec 2031 Term Corporate ETF (ARCA: IBDW)

에 대한 최신 뉴스 iShares iBonds Dec 2031 Term Corporate ETF (ARCA:IBDW)

The Fund seeks to meet its investment objective generally by investing in component securities of the Bloomberg Barclays December 2031 Maturity Corporate Index (the Underlying Index). The Fund may also invest in other exchange-traded funds (ETFs), U.S. government securities, short-term paper, cash and cash equivalents, including shares of money market funds advised by BFA or its affiliates.

iShares iBonds Dec 2031 Term Corporate ETF

Owens Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OC#NYSE">OC</a>), a building products leader, today announced that its Board of Directors has approved a new share repurchase authorization for up to 12 million shares of the company's common stock. The action reaffirms the company's capital allocation strategy and reflects the success of its disciplined commercial and operational execution to deliver consistent and sustainable performance in dynamic market conditions.
This authorization is in addition to the previously announced share repurchase program in which approximately 5.7 million shares remained available for repurchase as of March 31, 2025.

News

Owens Corning Board Approves New Share Repurchase Authorization For Up To 12M Shares

Biotech

General

ABEO

Abeona Therapeutics And Lurie Children's Open Center For ZEVASKYNTM Gene Therapy To Treat Wounds Associated With Recessive Dystrophic Epidermolysis Bullosa

Earnings

Earnings Beats

PDSB

PDS Biotechnology Q1 EPS $(0.21) Beats $(0.25) Estimate

Quoin Pharmaceuticals Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) (the "Company" or "Quoin"), a late clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announces positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome clinical study.
As the table below illustrates, after 12 weeks of treatment, clear evidence of skin healing in the area treated with QRX003 compared to baseline was observed.
<figure class="table"> 
<table>
<tbody>
<tr>
<td>End Point</td>
<td>Baseline</td>
<td>12 weeks (End of treatment period) &nbsp;</td>
</tr>
<tr>
<td>M-IASI&#x2A;</td>
<td>36</td>
<td>12 &nbsp;</td>
</tr>
<tr>
<td>IGA&#x2A;&#x2A;</td>
<td>4 (Severe)</td>
<td>2 (Mild) &nbsp;</td>
</tr>
<tr>
<td>CDQLI&#x2A;&#x2A;&#x2A;</td>
<td>19</td>
<td>11 &nbsp;</td>
</tr>
</tbody>
</table>
</figure>
 &#x2A;M-IASI: Modified Ichthyosis Area of Severity Index, a score used to assess the severity and extent of skin symptoms associated with ichthyosis. Lower scores indicate improvement. &#x2A;&#x2A;IGA: Investigator's Global Assessment, which uses descriptive categories (e.g., clear, mild, moderate, severe) to evaluate the overall severity of disease symptoms.
&#x2A;&#x2A;&#x2A; CDQLI: The Children's Dermatology Life Quality Index is a validated clinical tool designed for children aged 4-15 that is used to measure the impact of their skin disease on a child's quality of life in terms of symptoms, leisure activities, sleep, school, personal relationship and treatment. The scale for the CDQLI is 0-30.
QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial results, the patient is expected to continue to be treated with QRX003 with a further clinical assessment by the investigator scheduled after 24 weeks of treatment.

QNRX

Quoin Reports Early Data for Rare Skin Disease Treatment With No Adverse Events

Arcos Dorados Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARCO#NYSE">ARCO</a>) reported quarterly earnings of $0.07 per share which missed the analyst consensus estimate of $0.13 by 46.15 percent. This is a 50 percent decrease over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $1.08 billion which beat the analyst consensus estimate of $1.05 billion by 2.14 percent. This is a 0.41 percent decrease over sales of $1.08 billion the same period last year.

Earnings Misses

ARCO

Arcos Dorados Holdings Q1 EPS $0.07 Misses $0.13 Estimate, Sales $1.08B Beat $1.05B Estimate

Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ
RNA sequencing data show early tumor apoptosis and activation of innate immune responses
Updated ReSPECT data presented at the 2025 Nuclear Medicine and Neurooncology Conference
HOUSTON, May 14, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=NFvPtjrMT2cxlwT9EYDcpmv5A_g2fAoFWMszoLPF1HUlMZgqEZgs7ghCw8v2brzCKMAt2MDrj2u8CMIEd-zZJQXJ56OG7oRamFCSnxIqj-zJ7sfNwuIhnMRMhQA86p3F">Plus Therapeutics, Inc.</a> (Nasdaq:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=khU81DaUZRrYBaFqq__KNV3OgsLR1WfvFvRFX5PV7tkIF_m7OhBi_1SKqUVn0eB5XQpGlcuRfQ4o3laDOgfmjg==">PSTV</a>) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, announces the presentation of new data on its lead drug REYOBIQ&#x2122; (rhenium Re186 obisbemeda) during both an oral presentation and a poster presented at the Nuclear Medicine and Neurooncology Conference. The meeting was held May 9-10, 2025 in Vienna, Austria.

PSTV

Plus Therapeutics: REYOBIQ Shows Clinical Benefit And Safety In ReSPECT-LM Clinical Trial For Patients With Leptomeningeal Metastases

Needham analyst Gil Blum reiterates Fate Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATE#NASDAQ">FATE</a>) from Hold to Hold.

Reiteration

Analyst Ratings

FATE

Needham Reiterates Hold on Fate Therapeuticsto Hold

WIIM

American Eagle Outfitters shares are trading lower after the company guided Q1 revenue down and withdrew FY25 guidance.

Jefferies analyst Omar Nokta maintains Danaos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) with a Buy and raises the price target from $100 to $105.

Price Target

Jefferies Maintains Buy on Danaos, Raises Price Target to $105

Jeff Bezos vaulted onto the Forbes billionaire list at 34 because he did one thing most rising Wall Street stars wouldn't risk.
What Happened: The Princeton-trained computer scientist, class of '86, left hedge-fund D.E. Shaw as a vice president in 1994 after spotting a report that "Web usage was growing at 2,300 percent per year." "I'd never seen or heard of anything that grew that fast," he <a href="https://www.princeton.edu/news/2010/05/30/2010-baccalaureate-remarks">later recalled</a> in a 2010 speech at Princeton.
Bezos, 30, drove from New York to Seattle, <a href="https://www.benzinga.com/general/education/23/07/33119760/amazon-was-founded-29-years-ago-today-if-you-invested-1-000-in-amazon-stock-at-ipo-in-1997-here">seeded the venture</a> with $10,000 of his cash and lined up $84,000 in interest-free loans. Working from a rented garage, he launched Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) on July 16, 1995. Within two months, the online bookstore was booking $20,000 a week in orders.
The company went public on May 15, 1997, at $18 a share. A year later, Amazon's soaring stock put Bezos on Forbes' rich list with a net worth of $1.6 billion.
See also: <a href="https://www.benzinga.com/tech/25/05/45397728/youtube-scores-nfl-first-chargers-game-in-brazil-to-stream-free-worldwide">YouTube Scores NFL First: Chargers Game In Brazil To Stream Free Worldwide</a>
What To Know: Bezos' instinct to leap first has paid compounding dividends. He was the world's <a href="https://www.benzinga.com/news/17/07/9834929/jeff-bezos-adds-worlds-richest-person-to-achievements-a-chart-of-his-career">wealthiest person</a> from 2017 to 2021, according to Forbes, before ceding the crown to Tesla and SpaceX CEO Elon Musk. Today, Bloomberg's Billionaire index pegs him at roughly $232 billion, ranking him No. 2 globally.
Bezos often frames the gamble as a "<a href="https://www.benzinga.com/news/24/07/39666069/jeff-bezos-described-his-unique-life-philosophy-which-follows-a-dorky-framework-revolving-regret-min">regret-minimization framework</a>" — a calculation that failing would sting less than never trying. Three decades later, Amazon commands a market value above $2.2 trillion and has made its founder one of history's richest entrepreneurs — all because he decided the surest path to wealth was walking away from a sure thing.
Photo Courtesy: Lev Radin on Shutterstock.com
Read next: <a href="https://www.benzinga.com/markets/equities/25/05/45397896/roger-federer-backed-on-holding-jumps-12-as-dtc-sales-soar-sneaker-price-hikes-coming-to-offset-tariffs-and-fuel-premium-growth">Roger Federer-Backed On Holding Jumps 12% As DTC Sales Soar —Sneaker Price Hikes Coming To Offset Tariffs And Fuel Premium Growth</a>

Startups

AMZN

Jeff Bezos Became A Billionaire After Taking This Leap Of Faith: Would You Have The Stomach For His 'Regret-Minimization' Strategy?

Everus Construction Group shares are trading higher after the company reported better-than-expected Q1 financial results.

Needham analyst David Saxon reiterates Alcon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALC#NYSE">ALC</a>) with a Buy and maintains $110 price target.

Needham Reiterates Buy on Alcon, Maintains $110 Price Target

EXEL

Exelixis shares are trading higher after the company reported better-than-expected Q1 financial results and raised its FY25 sales guidance with its midpoint above estimates. The company, acting as a collaboration partner of Invenra, initiated the dose-escalation stage of the first-in-human Phase 1 clinical study of XB628.

DAVA

Endava shares are trading lower after the company lowered its FY25 guidance.

Alcon shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 adjusted EPS guidance below estimates.

Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) lowers FY2025 Adj EPS guidance from $1.54-$1.58 to $1.40-$1.42 vs $121.58 analyst estimate. Lowers FY2025 sales outlook from $1.02 billion-$1.02 billion to $971.13 million-$973.64 million vs $793.02 million estimate.

Guidance

Endava Lowers FY2025 Adj EPS Guidance from $1.54-$1.58 to $1.40-$1.42; Lowers FY2025 Sales Guidance from $1.02B-$1.02B to $971.13M-$973.64M

Needham analyst James Ricchiuti reiterates 3D Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDD#NYSE">DDD</a>) from Hold to Hold.

Needham Reiterates Hold on 3D Systo Hold

Sony Group Corporation American Depositary Shares

SONY

Sony Group shares are trading higher after the company reported better-than-expected Q4 EPS results.

The most oversold stocks in the materials sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">IT Tech Packaging Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>)</h3>
<ul class="wp-block-list">
<li>On May 13, IT Tech Packaging announced a $1.4 million public offering. The company's stock fell around 39% over the past five days and has a 52-week low of $0.15.</li>
<li>RSI Value: 28.1</li>
<li>PMTS Price Action: Shares of IT Tech Packaging fell 53.7% to close at $0.16 on Tuesday.</li>
<li>Edge Stock Ratings: 16.73 Momentum score with Value at 89.11. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/itp"><img loading="lazy" decoding="async" width="477" height="177" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042128/image-152.png" alt="" class="wp-image-914598" style="width:375px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042128/image-152.png 477w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042128/image-152-300x111.png 300w" sizes="(max-width: 477px) 100vw, 477px" /></a></figure>
<h3 class="wp-block-heading">Trinseo PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSE#NYSE">TSE</a>)&nbsp;</h3>
<ul class="wp-block-list">
<li>On May 7, Trinseo reported worse-than-expected first-quarter sales results. Frank Bozich, President and Chief Executive Officer of Trinseo, said, &#8220;Core business results in the first quarter were in line with expectations, and sequentially higher due to prior quarter customer destocking and seasonality. Despite persistent market weakness, the first quarter was Trinseo&#8217;s 7th consecutive quarter of year-over-year Adjusted EBITDA improvement driven by the various management actions we took early in this industry downturn.&#8221; The company's stock fell around 41% over the past five days and <a href="https://www.benzinga.com/quote/TSE">has a 52-week low</a> of $1.94.</li>
<li>RSI Value: 29.6</li>
<li>TSE Price Action: Shares of Trinseo fell 1.2% to close at $2.51 on Tuesday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">TSE stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="922" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042246/image-153.png" alt="" class="wp-image-914602" style="width:556px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042246/image-153.png 922w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042246/image-153-300x273.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042246/image-153-768x700.png 768w" sizes="(max-width: 922px) 100vw, 922px" /></a></figure>
<h3 class="wp-block-heading">Ascent Industries Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACNT#NASDAQ">ACNT</a>)</h3>
<ul class="wp-block-list">
<li>On May 12, Ascent Industries posted a first-quarter loss of 10 cents per share, versus a year-ago loss of 41 cents per share. &#8220;In Q1 2025, we built on our 2024 self‑help initiatives to double gross profit to $4.8 million and expand gross margin by 1,120 basis points to 19.4%, even as net sales held at $24.7 million,&#8221; said Ascent CEO Bryan Kitchen. The company's stock fell around 10% over the past five days and has a 52-week <a href="https://www.benzinga.com/quote/ACNT">low of $8.16</a>.</li>
<li>RSI Value: 20.6</li>
<li>ACNT Price Action: Shares of Ascent Industries fell 7.2% to close at $11.90 on Tuesday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514">ACNT shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0514"><img loading="lazy" decoding="async" width="885" height="843" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042347/image-154.png" alt="" class="wp-image-914604" style="width:590px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042347/image-154.png 885w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042347/image-154-300x286.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14042347/image-154-768x732.png 768w" sizes="(max-width: 885px) 100vw, 885px" /></a></figure>
Curious about other BZ Edge Rankings? Click here to discover how <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">similar stocks measure up</a>. 
Read This <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Next: </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

Trading Ideas

ACNT

Top 3 Materials Stocks That Could Blast Off This Month

Endava (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAVA#NYSE">DAVA</a>) is looking for Q4 Adj EPS of $0.28-$0.30 vs $0.34 analyst estimate. sees sales of $234.128 million-$236.645 million vs $202.55 million analyst estimate.

Comments

iShares iBonds Dec 2031 Term Corporate ETF

뉴스

에 대한 최신 뉴스 iShares iBonds Dec 2031 Term Corporate ETF (ARCA:IBDW)

뉴스

파트너 / 기고자

벤징가 글로벌